Amol Akhade: Next-generation KRAS G12C inhibitors are reshaping precision oncology
Amol Akhade, Senior Consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared a post on LinkedIn:
“Next-generation KRAS G12C inhibitors are reshaping precision oncology!
D3S-001, a next-gen GDP-bound inhibitor, is showing highly promising results:
Key takeaways:
- Higher ORR in both NSCLC and CRC compared to first-gen agents.
- Strong CNS penetration and early ctDNA clearance.
- Durable activity even post-G12Ci exposure.
Despite the success of agents like sotorasib and adagrasib, unmet needs persist — especially regarding CNS metastases, durability of response, and CRC efficacy without combination EGFR blockade.
D3S-001 appears poised to challenge the current standard and could become a potential backbone for KRASG12C-mutated cancers.
Full comparison chart attached below!
Question for the community:
- Are we entering a next-generation era where KRASG12C inhibitors will match or even outperform therapies like EGFR TKIs in lung and colorectal cancers?
Will these ORR convert into OS Benifit?”
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023